AEterna Zentaris (NASDAQ:AEZS) Earning Somewhat Positive News Coverage, Analysis Shows

Media headlines about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.3031995344878 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

AEterna Zentaris (AEZS) opened at 2.16 on Tuesday. The firm’s 50 day moving average price is $2.04 and its 200 day moving average price is $1.76. AEterna Zentaris has a 52-week low of $0.78 and a 52-week high of $5.59. The firm’s market cap is $34.80 million.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.05). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. AEterna Zentaris had a negative net margin of 1,945.78% and a negative return on equity of 514.64%. AEterna Zentaris’s revenue for the quarter was up 153.1% compared to the same quarter last year. Equities research analysts anticipate that AEterna Zentaris will post ($1.02) EPS for the current fiscal year.

Several research firms have issued reports on AEZS. Maxim Group set a $4.00 price objective on AEterna Zentaris and gave the stock a “buy” rating in a report on Friday, August 11th. ValuEngine upgraded AEterna Zentaris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the company a “buy” rating in a report on Wednesday, July 5th. Finally, Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $4.33.

WARNING: “AEterna Zentaris (NASDAQ:AEZS) Earning Somewhat Positive News Coverage, Analysis Shows” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Insider Buying and Selling by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply